Stock OTLC ONCOTELIC THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Oncotelic Therapeutics, Inc.

Equities

OTLC

US6283411097

Market Closed - OTC Markets
Other stock markets
 20:29:23 28/06/2024 BST 		5-day change 1st Jan Change
0.0325 USD -1.52% Intraday chart for Oncotelic Therapeutics, Inc. -7.14% -15.14%
05-15 Oncotelic Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-12 Oncotelic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Oncotelic Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Oncotelic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Oncotelic Therapeutics, Inc. Announces Linkage of Cancer and Lupus in Gliomas Patients
Oncotelic Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Oncotelic Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Oncotelic Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Oncotelic Launches PDAO SEC chatbot
Oncotelic Therapeutics and Vectara Announce Strategic Partnership to Transform Pharmaceutical Research with Large Language Model Technology
Oncotelic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Oncotelic Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt
Oncotelic Therapeutics, Inc Announces The Publication of High Intra-Tumor Transforming Growth Factor ?2 Level as A Predictor of Poor Treatment Outcomes in Pediatric Cancer of the Brainstem
Oncotelic Therapeutics, Inc. Announces Executive Changes
Oncotelic Announces Initiation of Clinical Study in Non-Small Lung Cell Cancer
Oncotelic Therapeutics, Inc. Initiates Clinical Trials Evaluating OT-101 against Metastatic Pancreatic Cancer
Oncotelic Therapeutics, Inc. Announces Launch of Wholly Owned Subsidiary, Pet2DAO Inc. and its Associated Token PDAO
Oncotelic Therapeutics, Inc. Presents Clinical Data of Confirming TGF-BETA>2 as the Appropriate Target for Gliomas At JCA-AACR Meeting 2022
Oncotelic Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Oncotelic Initiates Clinical Trials Evaluating OT-101 Against Pediatric Gliomas
Oncotelic Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
Oncotelic Therapeutics Receives FDA Clearance for Phase 2 Clinical Trial of OT-101/Pembroluzimab Combination for Mesothelioma
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OTLC Stock
  4. News Oncotelic Therapeutics, Inc.
  5. Other languages